Professor Dror Dicker, co-lead author from Hasharon Hospital at Rabin Medical Centre in Israel ... Research has indicated that GLP-1 receptor agonists, such as Ozempic and Wegovy, could lower the risk ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

The announcement follows new research that suggested drugs like Wegovy, Mounjaro and Ozempic slashed the risk of contracting the disease. Scientists from Israel said the drugs, also known as GLP ...

Scientists herald 150 new jabs and pills to tackle obesity going through the research pipeline - but issue urgent warning to ...

The findings come after reports of nasty side effects - including eye problems, infections and gastrointestinal disorders - ...

Studies suggest these drugs can reduce body weight by up to 22.5% over 72 weeks hence, it is crucial to be aware of potential risks and side ... data is needed.” Ozempic, a drug for diabetics ...

Bad reactions to popular weight-loss drugs, including Ozempic and Wegovy ... a week later she was rushed to hospital after experiencing 'massive blood clots'. She was then referred to a colorectal ...

Ozempic, a diabetes drug ... constipation, and possible risks for pancreatitis or gallbladder issues in some people. So, it’s not a universal fix—but it could be a huge step forward for ...

The team reviewed electronic health records (EHRs) from more than 100 million patients in the US, including over 20,000 who were taking Ozempic. They looked at their risk of developing ...

The explosive popularity of GLP-1 (Glucagon-Like Peptide-1) drugs for addressing weight loss, diabetes and obesity, such as Ozempic and Munjaro are useful for a limited number of people and will ...